Loading
Medical Imaging Techniques and Applications · Journal article
Journal of Sustainable Smart Systems in Education & Environment · September 4, 2026
A consensus or society position rather than new primary data.
This is a narrative review describing established clinical applications of radioisotopes (iodine-131, technetium-99, lutetium-177, radium-223) in nuclear medicine for diagnosis and targeted cancer treatment. The source presents no original experimental or clinical data, comparative effectiveness evidence, or quantified outcomes, and therefore does not constitute evidence for or against the efficacy of these modalities.
Journal article. Cancer patients undergoing diagnosis or treatment with nuclear medicine, generalized to thyroid, heart, bone, and prostate pathology.
Iodine-131 and technetium-99 are commonly used for thyroid and cardiac imaging, respectively Iodine-131 is applied in treatment of thyroid cancer Lutetium-177 and radium-223 are used in treatment of bone tumors and prostate cancer, respectively
No efficacy data, survival rates, response rates, or adverse event frequencies reported
This review provides background on established radioisotope applications but does not supply efficacy data, outcome measures, or comparative evidence to inform clinical decision-making. Clinicians should refer to primary trial data and clinical guidelines for evidence-based practice guidance.
This is a descriptive review article outlining established clinical applications of radioisotopes in nuclear medicine diagnosis and treatment, presenting expert-level information without reporting new empirical data or comparative evidence.
This review provides background on established radioisotope applications but does not supply efficacy data, outcome measures, or comparative evidence to inform clinical decision-making. Clinicians should refer to primary trial data and clinical guidelines for evidence-based practice guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The application of radioisotopes in nuclear medicine represents a modern technology that significantly impacts diagnosis and treatment, particularly in cancer care. In diagnosis, the use of radioisotopes for imaging organs and tumors involves small quantities injected into the body to show regions of high biological activity, enabling one to accurately determine the positions of tumors. These include "iodine-131" and "technetium-99", which are commonly used for imaging the thyroid and heart, respectively. In this way, such images reveal to the doctor the functions of organs and allow him to assess the extent of tumor spread, thereby contributing to an accurate treatment plan. The therapeutic applications in treatment depend on the targeting of cancerous cells with specific dosages of radiation using selected radioactive isotopes. Radiation destroys either the cancer cells or shrinks tumors, while there is minimal injury to the healthy body tissue. Iodine-131 is applied in treatments for thyroid cancer, whereas lutetium-177 and radium-223 are other radioactive isotopes used in treatments for bone tumors and prostate cancer, respectively. These treatments allow radiation to be focused precisely at the diseased cells, which offers a greater efficacy in treatment with a lesser set of side effects that may arise from the use of more conventional forms of radiation therapy. Nuclear medicine can thereby create a bright future in improving the survival rates and lifestyles of patients. Simultaneously, it will contribute to offering avant-garde therapeutic solutions that also include consideration for individuality in treatment. With further development in this field, radio-isotope applications are envisaged to expand and bring up new frontiers for diagnosis and treatment in the future.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.